Drug Discovery Strategies

Using Mass Spectrometry for Drug Metabolism Studies 

FIGURE 2.4 The NCE success rates from 2003 to 2007 for each phase of drug development. Less than 10% of lead compounds are approved. (Courtesy of KMR Group, Chicago, IL and the Pharmaceutical Benchmarking Forum. With permission.) 

---

Fig. 14.2 Different drug discovery strategies (A) Sequential optimization (historic approach) - first optimization of affinity, while ADME properties are treated at a later stage. (B) Multidimensional scenario - combined optimization of affinity and ADME properties, simultaneous monitor changes in relevant properties [20],...

Campbell, S. and Differding, E. Drug discovery strategies from leads to drugs. Chitn. Nouv. 2001, 19, 3347-3352. 

Makiryannis, Alexandres, and Diane Biegel. Drug Discovery Strategies and Methods. New York Marcel Dekker, 2004. 

Drug Discovery Strategies Focusing on Disease-Related Carbohydrates. 2388... 

In a first order, drug discovery strategies can be divided into the following parts ... 

Optimization of drug discovery strategies is driven by the actual patent situation (drug discovery and development 10 to 12 years term of patent 20 years expiry of important patents in the next few years will cause drastic drops in turnover) forcing the companies to shorten the time taken to bring a drug onto the market. 

Koch, C. Neumann, T. Thiericke, R. Grabley, S. A Central Natural Product Pool—New Approach in Drug Discovery Strategies, Drug Discovery from Nature, Chapter 3, 51-55, Susanne Grabley and Ralf Thiericke, eds, Berlin, Springer (1999). 

It could be argued that drug discovery strategies of the past were analogous to fishing with a line and hook. A systematic series of trial and error experiments such as quantitative structure-activity relationship (QSAR) methodologies, for example, were commonplace. The process was iterative and labor intensive. A chemist or biologist had relatively few restrictions, particularly with time, to explore ideas and test hypotheses. The overall endeavor was more craft than process. 

Makriyannis A, Goutopoulos A (2004) Cannabinergics old and new therapeutic possibilities. In Makriyannis A, Biegel D (eds) Drug discovery strategies and methods. Marcel Dekker, New York, pp 89-128... 

---